Drug discovery

#Biotechnology #Drug discovery #High throughput screening #Whitepaper

High-throughput screening for small molecule drug discovery

High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery. In this whitepaper, “Disrupting Drug Discovery From Assay Development to Lead Compound”, SAMDI Tech CSO, Zack Gurard-Levin, discusses the important aspects to consider when choosing the right methodology for drug discovery. The whitepaper covers traditional… Read More

#News

#AI / data analytics / healthtech / informatics #Deep learning #Drug discovery #Pharmaceutical

Opportunities and challenges for AI in drug discovery

By Naheed Kurji, Co-founder and Executive of the Alliance for Artificial Intelligence in Healthcare (AAIH), CEO of Cyclica; and Andreas Windemuth, Ph.D, Chief Science Officer of Cyclica Over the past decade, a new industry has arisen that seeks to apply artificial intelligence (AI), or more aptly machine learning (ML) technologies,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

#Biotechnology #Diagnostics #Drug discovery #Immunology #Immunology / Virology & Vaccines #Pandemic

University of Oxford to launch Pandemic Sciences Centre

The University of Oxford has announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats. Read More

#News #Trending News

#Drug discovery #Infectious diseases #Life sciences #Research

Millions invested to help life sciences fight infectious disease

The UK’s centre for therapeutics innovation, Medicines Discovery Catapult (MDC), has received a £5 million grant to build a Translational Research Facility in Infectious Disease on its Alderley Park site, as part of the government’s Getting Building Fund programme. Actively seeking collaborations with SMEs, academics and others in infectious disease… Read More

#News

#Antibodies #Biotherapeutics #Drug discovery #Drug targets #Genovac

Berkeley Lights: Improving antibody discovery

John Proctor, Senior Vice President of Antibody Therapeutics at Berkeley Lights, and Brian Walters, President/CEO of Genovac Antibody Discovery, talk with DDW’s Megan Thomas about the company’s new Beacon system, which the CRO believes may be the new gold standard in antibody discovery with the potential to up antibody discovery. Read More

#Editor's Choice #Exclusive Content #News

#Data #Drug discovery #Drug screening #Screening #Whitepaper

Expertise on analysis of targeted protein degrader compounds

Small molecule drug discovery is expanding beyond traditional strategies focused on identifying compounds that inhibit or block the activity of proteins that cause disease, says Promega. A newer approach to small molecule drug discovery is to selectively target proteins for removal from the cell using degrader compounds, focussing on identifying… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Drug candidates #Drug design #Drug discovery #Research

AI accelerates discovery of small molecule drug candidates

Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb Company. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in… Read More

#News

#Drug development #Drug discovery #Malaria #Research

Malaria stopped in its tracks with new drug compound

Researchers at the Francis Crick Institute and the Latvian Institute of Organic Synthesis have designed a drug-like compound which effectively blocks a critical step in the malaria parasite life cycle and are working to develop this compound into a potential first of its kind malaria treatment. While drugs and mosquito… Read More

#News

#AI #Biobanking #Drug development #Drug discovery #Machine learning #Narrated podcasts

Precision medicine in the era of artificial intelligence

This is the latest episode of the free DDW podcast, “Precision medicine in the era of artificial intelligence”. It covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh, who discuss the value… Read More

#Podcasts

#3D modelling #Antibiotics #Biotechnology #Cell / tissue culture #Data #Drug discovery #Drug targets #Drug technology #Imaging

How imaging techniques are innovating drug discovery

Lu Rahman takes look at some of the latest imaging innovation available and how it can benefit drug target identification and drug discovery research. Imaging is an important element within the drug discovery and development process providing researchers with information that can help identify potential drug targets or see how… Read More

#Exclusive Content #News #Trends & Analysis

#Drug development #Drug discovery #ELRIG #Events #Life sciences

Weather the Storm: Drug Discovery and the ELRIG community

On May 27, 2021, ELRIG’s “hot topic” webinar, Weathering the Storm: Drug Discovery & the ELRIG Community takes place virtually. Scientists, medical professionals, business leaders and others associated with the life sciences, which ELRIG consider to be the core of their drug discovery community, and who, throughout the pandemic, have… Read More

#News

#Drug discovery #Gene sequencing #Genome sequencing #Sequencing

Macrogen Europe expands sequencing capacity

Genomic sequencing service provider Macrogen Europe has achieved an upgrade to its next generation sequencing (NGS) capacity. The installation of an additional Illumina NovaSeq 6000 high-throughput sequencing system in its headquarters in the Netherlands helps manage increased demand with high-quality results and fast, reliable turnaround times. The addition of the… Read More

#News

#Alzheimer's #Clinical trial #Drug development #Drug discovery #Drug targets #Immuno-oncology

Can this clinical trial move us closer to an Alzheimer’s treatment?

Exscientia has announced a Phase I clinical study of DSP-0038 in the US for the treatment of Alzheimer’s disease psychosis. DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma… Read More

#News

#Assay #Bioscience #Data #Drug discovery #Drug targets #Interview #Life sciences #Screening

Ask the expert: assisting researchers with hit-to-lead

Pelago Bioscience is a specialised CRO, focusing on its patented Cellular Thermal Shift Assay (CETSA), which can assess therapeutically relevant target engagement in cells or tissue of unmodified compounds against the native, full-length proteins of interest. Stina Lundgren, Principal Project Advisor, shared the company’s hit-to-lead expertise with Lu Rahman. CETSA… Read More

#Editor's Choice #Exclusive Content #News

#Biologics / Biotechnology #Cell sequencing #DNA #Drug development #Drug discovery #Genome editing #Genome sequencing #Life sciences #Sequencing #Synthetic biology

The new synthesis: How synthetic DNA technology is changing drug discovery

Listen to this article on the DDW Podcast: Dr Tim Brears, CEO, Evonetix and Dr Raquel Sanches-Kuiper, Director of Biology, Evonetix explore applications of synthetic DNA in drug discovery and development, the benefits and limitations of current methods, and the opportunities offered by emerging DNA synthesis technologies. On 16… Read More

#Editor's Choice #Exclusive Content #News #Opinion